review Open AccessTop 1% cited
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
European Journal of Pharmacology · 2014 · Vol. 741 · pp. 8–16
Lucas de Sousa Cavalcante✉(Universidade de São Paulo)Gisele Monteiro(Universidade de São Paulo)
Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsEpigenetics and DNA MethylationGemcitabinePancreatic cancerAdenocarcinomaMedicineOncologyInternal medicineChemotherapyCancerCancer research
MeSH terms
GemcitabineAnimalsAntimetabolites, AntineoplasticDeoxycytidineHumansPancreatic NeoplasmsInflammation MediatorsDrug Resistance, Neoplasm
Funding
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Universidade de São Paulo
Citations
580
FWCI
13.12
field-weighted impact
References
120
Percentile
99%
vs. same field & year
Citations per year
Cited by
Pancreatic Cancer Chemoresistance to Gemcitabine
Cancers · 2017 · 445 citations
References
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Clinical Cancer Research · 2010 · 1,452 citations
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Trends in Pharmacological Sciences · 2012 · 1,508 citations
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
New England Journal of Medicine · 2011 · 7,636 citations
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
New England Journal of Medicine · 2013 · 6,561 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.